{
    "title": "110_hr1902",
    "content": "The \"Protecting Consumer Access to Generic Drugs Act of 2007\" addresses unfair and deceptive practices related to new drug applications. The \"Protecting Consumer Access to Generic Drugs Act of 2007\" prohibits agreements where an ANDA filer receives value and agrees not to market the drug subject to a patent infringement claim, with exceptions allowing limited rights to market the drug before the patent expires. The \"Protecting Consumer Access to Generic Drugs Act of 2007\" prohibits agreements related to patent infringement claims and grants waivers for prior marketing of drugs. Violations are considered unfair and deceptive acts under the Federal Trade Commission Act. The \"Protecting Consumer Access to Generic Drugs Act of 2007\" prohibits agreements related to patent infringement claims, defining terms like \"agreement,\" \"agreement resolving or settling,\" \"ANDA,\" \"ANDA filer,\" and \"patent infringement.\" The term \"patent infringement\" encompasses various forms of patent violations, while a \"patent infringement claim\" refers to any allegation made to an ANDA filer regarding potential patent infringement. The Federal Trade Commission can exempt certain agreements under section 2 if they promote market competition and benefit consumers. The Commission has the authority to issue rules and policies related to prohibited practices. Additionally, amendments are made to the 180-day exclusivity period forfeiture under the FFDCA. In a declaratory judgment action, a court can dismiss the case for lack of subject matter jurisdiction, with or without prejudice. SEC. 5. NOTICE AND CERTIFICATION OF AGREEMENTS. The applicant files a covenant with the Secretary by the patent owner not to sue for infringement regarding the patent. In subclause (V), it is stated that the agreement has violated the Protecting Consumer Access to Generic Drugs Act of 2007. Section 1112 of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 is amended to include a description of any additional agreements entered into within 30 days of the initial agreement. The Chief Executive Officer or company official must certify and file any agreements required under subsections (a), (b), or (c) with the Assistant Attorney General and the Commission. The Assistant Attorney General and the Commission require a certification stating that all agreements filed under section 1112 of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 are complete, final, and exclusive, including any related ancillary agreements and written descriptions of oral agreements."
}